InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.059 0.002 (3.51%)+
Announcement
Release
31 Jul 2026 3:32PM
Price at Release
$0.057
Full Release
download
Summary
Neurizon Therapeutics Limited, an Australian biotech company, provided its quarterly activities report and Appendix 4C for Q4 FY26. The company reported significant progress in its clinical, scientific, and corporate development activities, particularly in the Phase 2/3 HEALEY ALS Platform Trial, where Regimen I expanded to 250 participants. Despite the expansion, funding requirements remain unchanged due to support from the Sean M. Healey & AMG Center for ALS. Neurizon executed a long-term supply agreement with Elanco Animal Health for the active ingredient monepantel, improving commercial readiness and reducing manufacturing risks. Financially, Neurizon had operating outflows of $6.4 million and held $12.7 million in cash as of 30 June 2026. The company also established a strategic R&D financing facility of up to $17.5 million with Dare Capital, secured against its R&D Tax Incentive refund, while raising an additional $2.7 million through a placement. Upcoming milestones include the completion of HEALEY RCT and the presentation of new preclinical data.
Key Points
  • Neurizon expanded the HEALEY ALS Platform Trial Regimen I to 250 participants.
  • Long-term supply agreement with Elanco Animal Health secured.
  • No change in funding requirements due to philanthropic support.
  • Operating cash outflows were $6.4 million for the quarter.
  • Held $12.7 million in cash at the end of Q4 FY26.
  • Established a $17.5 million R&D financing facility with Dare Capital.
  • Raised approximately $2.7 million through a placement.
  • Upcoming milestones include HEALEY RCT completion and new preclinical data presentations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.